Vanda Pharmaceuticals | VNDA - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
Acadia Pharmaceuticals USD 148.57M 12.22M 2026-06
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Akebia Therapeutics USD 23.53M 3.19M 2025-12
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 46.63M 4.88M 2026-06
AstraZeneca USD 5.8B 735M 2026-06
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Eli Lilly USD 3.43B 496M 2026-06
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Halozyme Therapeutics USD 57M 10.71M 2026-06
Heron Therapeutics USD 23.74M 605K 2025-12
Insmed USD 247.47M 208K 2026-06
J&J USD 6.42B 381M 2026-06
Lexicon Pharmaceuticals USD 3.98M 195K 2025-12
Ligand Pharmaceuticals USD 29.12M 8.29M 2026-06
Merck USD 2.89B 219M 2026-06
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Moderna USD 216M 43M 2026-06
Novartis USD 3.14B 296M 2026-03
Pfizer USD 3.41B 496M 2026-06
PTC Therapeutics USD 73.89M 13.31M 2026-03
Puma Biotechnology USD 16.82M 8.15M 2024-09
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.63B 307M 2026-06
Takeda JPY 286.51B 5.48B 2026-06
Teva Pharmaceutical Industries USD 1.03B 34M 2026-06
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12
Veracyte USD 55.71M 4.87M 2026-06